

Company name **Compugen Ltd.** Website <https://cgen.com/>

CEO name Anat Cohen-Dayag

Cell phone number +972-525989880

Select a CATEGORY: **Biotech/Pharma**

Select up to two SESSIONS per abstract from the list below

- 3. Are Cancer Therapeutics Fulfilling the Promise?
- 12. Bio Convergence - Everything That Rises Must Converge.

- **Executive Summary / Investment Rational**

- Compugen is a clinical-stage drug-discovery company utilizing its broadly applicable, predictive computational discovery platforms to identify novel biological pathways and drug targets and develop biologics therapeutics in the field of cancer immunotherapy. Compugen's innovative pipeline consists of multiple programs, three of which are at clinical stage development, two internal and one in collaboration with AstraZeneca.

- **Core Technology**

- Compugen's unique value proposition is based on its broad and innovative computational-discovery capabilities, which are complemented by extensive research, drug-discovery, and clinical expertise. These are validated by collaborations with prominent industry and academic leaders in the IO space and have conjured an innovative immuno-oncology portfolio with few internally discovered new drug targets that progressed to clinical testing in patients.

- **Product Profile/Pipeline**

- Compugen's pipeline consists of computationally discovered early and clinical-stage programs of drug-targets aiming to address the significant unmet need of resistant cancer patient population. Our lead wholly-owned assets: COM701 and COM902, demonstrated initial signs of anti-tumor activity in heavily pre-treated cancer-patients with tumors which are typically non-

responsive to immunotherapy. COM503 is an additional potential; first-in-class asset at the IND-enabling stage.

- **Business Strategy**

- Compugen seeks to leverage its existing and constantly evolving pipeline of internally discovered product candidates to enter various forms of revenue-sharing collaborative arrangements, with the aim to advance its early- and clinical-stage programs and bring transformational therapies to patients.

- **What's Next?**

- Compugen is currently expanding its Phase 1 clinical trials in two difficult-to-treat focused indications where initial clinical signals were observed: microsatellite-stable colorectal cancer and platinum-resistant ovarian cancer. In parallel, Compugen is advancing its earlier stage pipeline, consisting of multiple novel target programs, including COM503 development towards IND as well as seeking additional business opportunities.